Operator: Thank you. We will now go to our next question. And your next question comes from the line of Graham Doyle from UBS. Please go ahead.
Graham Doyle: Good morning, guys. Thanks for taking the questions. Just one on the consent decree and then just one on the testing. With regards to the consent decree, you very helpfully gave us a bit of an update in terms of the dynamics about two months ago where you sort of — I think, Abhijit, you were describing as a process whereby the FDA is reaching out every month or so and asking you some questions about new topics and then updating the draft consent decree. I just love to get an understanding as to where we are in relation to that. So, we are still in that process of more questions, more answers, and another update to the draft and — or are we pushed on beyond that? And then secondly with relation to the testing.
So, I think it’s kind of interesting, you are still referring to the data is showing no appreciable harm to patients. It just seems there’s a bit of a gap between that and then obviously the statement the FDA put out around requiring more tests to fully evaluate the risk posed to users. So, is there a gap between you two guys or am I sort of misunderstanding that? Thank you.
Abhijit Bhattacharya: Hi, Graham. Let me take the first one. We’ve — I think this whole speculation on the timing of the CD and the progress of the CD creates a lot of unnecessarily ripple which is why we said, you know, we don’t control the timeline and we will update you as soon as we know that the CD is done. So, I think we’d just like to leave it there. As soon as we — the CD is signed and it’s done, you will get to know all the details what they impact us — impact is on us. And in the meantime, we just don’t want to give any further update because it creates just too much unnecessary speculation.
Roy Jakobs: Yes. Maybe I will take the second one, on the testing. So, I think what’s important is that the FDA did not disqualify our testing to date, right? They acknowledge it’s extensive, it’s done with third parties and actually, they have also been looking into the data in great detail. The fact that they have some additional questions to be answered, actually, I see as very positive because actually if we can satisfy those, we can come to the same conclusions hopefully. And that’s in the interest of the patient and patient safety and kind of underwriting then the outcomes that we also have been presenting today. So, we are very confident in that because we put all the efforts in. We have a very scientific rigorous process followed to come to those tests, that there are additional questions, we are happy to address those.
We will do that in full collaboration and we also see actually this as a positive development because the clearer we can get on what is still outstanding to be answered, actually that helps us to take those questions off the table. And we of course remain at full disposal to do so.
Graham Doyle: Okay, super. Just one quick question on medical monitoring. I think again it’s sort of flagged as a 2024 potential update around that and that always seemed a bit more procedural to me. Is that progressing as you’d expect and is that a H1 event or is that more H2 as well?
Roy Jakobs: So, I think it’s — as we said, it’s progressing as we expected. So, the steps are taken by the judge and in the process. But we — I think it’s not very useful to speculate on exact timing, because it’s very hard to judge upon it. What we said is, we really hope that we can come forward in 2024 with some news around this part of the follow-up of the recall and that’s probably best to leave it there. When we have news, we will share it.
Graham Doyle: Okay. No, I appreciate that. Thanks a lot, guys.
Operator: Thank you. We will now go to the next question. And the next question comes from the line of Sezgi Bice Ozener from HSBC Germany. Please go ahead.
Sezgi Bice Ozener: Hi. Thanks for taking my questions. I will also have two, please. First of all, the one — first of all, a very detailed one actually. In Connected Care, you had further remediation costs and quality costs this quarter. Just would like to find out specifically what they relate to. And my second question is on the D&T side, the improvement you’ve seen this quarter, despite China. Can you a bit detail which parts were in the forefront as you described that lead times are increasing in MR? It looks more like Image Guided Therapy and probably Ultrasound to me. But some details as well as what the — what the pricing impact within this growth was, that’d be very helpful. Thank you.
Abhijit Bhattacharya: So, on the remediation cost, it was slightly higher this quarter. That was on certain smaller product lines which we decided not to remediate because the cost of remediation would just outdo the benefits that we would get. So, there were some inventory that we wrote-off related to that. So that triggered a slightly higher cost. On your question on D&T China, I think we are mixing a couple of things. Because in China, the issue is on order intake, right? The — there is no problem in terms of access to hospitals delivering on the existing order book, which is why China also grew pretty well in D&T in the quarter. So that is not an issue. The issue that we’ve flagged this for order intake, given the new procedures that are in place in China.
It just takes longer for it to come into our order intake. The funnel as Roy mentioned continues to remain very strong. What was the last part of your — did I answer your question, Sezgi, or is there a part that I’ve missed out?
Sezgi Bice Ozener: Actually, the D&T part was about the pricing impact.
Abhijit Bhattacharya: Sorry, I mentioned that…
Sezgi Bice Ozener: Into the strong quarter’s figure.
Abhijit Bhattacharya: Yes. Sorry, I mentioned that earlier, the pricing impact in the third quarter was about 1% or so. And that will pick up. This is the first time we see that the pricing from the order book starts coming into the P&L, and we will see that coming, let’s say, in further quarters a little bit more.
Sezgi Bice Ozener: Okay, thank you. I thought this was mentioned for Personal Health on the — it was the company-wide comment. Okay, thank you.
Abhijit Bhattacharya: Yeah. Thanks, Sezgi.
Operator: Thank you. We will now take our last question for today. And the last question comes from the line of Falko Friedrichs from Deutsche Bank. Please go ahead.
